3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
11
Neoplasms
2
Mycosis Fungoides
2
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphomatoid Papulosis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
47
Carboplatin
35
Paclitaxel
28
Specimen Handling
20
Cyclophosphamide
17
Capecitabine
16
Magnetic Resonance Spectroscopy
15
sacituzumab govitecan
13
Gemcitabine
13
Biopsy
13
Taxes
12
130-nm albumin-bound paclitaxel
11
Albumin-Bound Paclitaxel
9
olaparib
8
Doxorubicin
8
Nivolumab
7
fludarabine
6
Cisplatin
6
eribulin
5
atezolizumab
5
Radiotherapy
5
Docetaxel
5
durvalumab
4
Immunoglobulin G
4
Fulvestrant
4
Epirubicin
4
Drug Therapy
4
Bevacizumab
4
veliparib
3
toripalimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Brentuximab Vedotin
×
90 days
×
Clear all
No trials found.